Spinal cord hydrolysate ameliorate immunological reaction in experimental allergic encephalomyelitis

Acta Neurobiologiae Experimentalis

Volumn 69, Issue 1, 2009, Pages 73-78

  Kwiatkowska Patzer, Barbara ^a   Michalkiewicz, Jacek ^b,d   Kubiszewska, Izabela ^d   Zielińska, Joanna ^a   Kasarello, Kaja ^a   Kurzepa, Katarzyna ^c   Lipkowski, Andrzej W ^a,c  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Experimental allergic encephalomyelitis; Oral tolerance; Sclerosis multiplex

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; PROTEIN HYDROLYSATE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIG; HOSPITALIZATION; IMMUNOLOGY; LEWIS RAT; LYMPHOCYTE; METABOLISM; METHODOLOGY; RAT; SPINAL CORD; SPLEEN; TIME;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIGS; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOCYTES; PROTEIN HYDROLYSATES; RATS; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; SPINAL CORD; SPLEEN; TIME FACTORS;

EID: 65549169497     PISSN: 00651400     EISSN: 00651400     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cendrowski W (2004) Selected issues of immunomodulating treatment in multiple sclerosis. Neurol Neurochir Pol 38: 299-306.
2. Cuzner ML, Opdenakker G (1999) Plasminogen activators and matrix metalloproteinases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 94: 1-14.
3. Ewing C, Bernard CC (1998) Insights into the aetiology and pathogenesis of multiple sclerosis. Immunol Cell Biol 76: 47-54.
4. Friedman A, Wiener HL (1994) Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci U S A 91: 6688-6692.
5. Hauser SL (2005) An update on multiple sclerosis. J Neurol Sci 228: 193-194.
6. Higgins PJ, Weiner HL (1988) Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. J Immunol 140: 440-445.
7. Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to therapeutic pipelines. Proc Natl Acad Sci U S A 101 (Suppl 2): 14599-14606.
8. Jewell SD, Gienapp IE, Cox KL, Whitacre CC (1998) Oral tolerance as therapy for experimental autoimmune encephalomyelitis and multiple sclerosis: demonstration of T cell anergy. Immunol Cell Biol 76: 74-82.
9. Kelly KA, Whitacre CC (1996) Oral tolerance in EAE: reversal of tolerance by T helper cell cytokines. J Neuroimmunol 66: 77-84.
10. Kwiatkowska-Patzer B, Baranowska B, Walski M, Lipkowski AW (2003) Influence of spinal cord protein hydrolysate upon the blood brain barrier changes due to experimental allergic encephalomyelitis in Lewis rats. Ultrastructural study. Folia Neuropathol 41: 29-34.
11. Kwiatkowska-Patzer B, Walski M, Frontczak-Baniewicz M, Zalewska T, Baranowska B, Lipkowski AW (2004) Matrix metalloproteases activity and ultrastructural changes in the early phase of experimental allergic encephalomyelitis. The effect of oral treatment with spinal cord proteins hydrolysate in Lewis rats. Folia Neuropathol 42: 107-111.
12. Lassmann H (2005) Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 15: 217-222.
13. Lipkowski AW, Baranowska B, Marczak E, Kwiatkowska-Patzer B, Gajkowska B, Walski M (2000) Protein hydrolysates for oral tolerance. Biofactors 12: 147-150.
14. Losy J (2007) Cytokines in the pathogenesis of multiple sclerosis. Acta Neurobiol Exp (Wars) 67 (Suppl.): 276. (Abstr. S8.5).
15. Mowat AM, Steewl M, Worthy E, Kevin P, Garside P (1996) Inactivation of Th1 and Th2 cells by feeding ovalbumin. Ann N Y Acad Sci 778: 122-132.
16. Oderfeld-Nowak B, Zaremba M, Kwiatkowska-Patzer B, Lipkowski AW, Aloe L (2002) Progenitors of oligodendroglia in acute and chronic phase of experimental allergic encephalomyelitis(EAE).Glia.(Suppl. 1): Abstr. P331.
17. Oderfeld-Nowak B, Zaremba M, Lipkowski AW, Kwiatkowska-Patzer B, Triaca V, Aloe L (2003) High-affinity NGF receptor in the rat spinal cord during acute and chronic phases of experimental autoimmune encephalomyelitis: a possible functional significance. Arch Italien Biol 141: 103-116.
18. Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D (2005) Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol 165: 41-52.
19. Steinman L (2001) Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol 13: 597-600.
20. Sypecka J, Tarnowska A, Domanska-Janik K (2007) Hippocampal microenvironment instructs NG2 precursors to become neurons. Acta Neurobiol Exp (Wars) 67 (Suppl.): 295. (Abstr. P3.11).
21. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA (1994) Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12: 809-837.
22. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM (1991) Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 147: 2155-2163.
23. Zawada M, Pernak M, Liwen I, Januszkiewicz-Lewandowska D, Rembowska J, Jaworska- Kubica B, Hertmanowska H, Wender M, Nowak J (2006) The possible participation of MSR virus in etiology of multiple sclerosis. Acta Neurobiol Exp 66 (Suppl.): 404. (Abstr. SIV-01).